We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.017 | 1.04% | 1.646 | 1.622 | 1.698 | 1.70 | 1.646 | 1.70 | 636,931 | 08:01:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.66 | 18.61M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/1/2020 14:46 | sadly every good share it seems has a troll-he just has the fear of missing out syndrome.i v much doubt anyone takes him seriously,hes clearly unstable. | purple11 | |
25/1/2020 15:32 | I see he is aggrevating everyone on another thread. He must know that Hemogenyx will not be funding a Phase one trial, I am assuming he is not that thick. So he is being deliberately obtuse and is reveling in the attention he is receiving. If he was ignored he might eventually vanish. | nextlink | |
23/1/2020 12:03 | So how many years away to people think phase 1 trials could be? How much will hemo need to fundraise to get funding for it, it's very expensive. | davevt | |
22/1/2020 23:15 | Purple, Tweet from HEMO! hxxps://t.co/ailP7qY | marie1980 | |
21/1/2020 20:20 | think globalco and your peanut brain may be half way there..... | runwaypaul | |
21/1/2020 19:14 | It's just hilarious! | davevt | |
21/1/2020 15:40 | fair play old boy.just need to get into phase1 trials and this target starts to become a reality. gl | purple11 | |
21/1/2020 15:39 | £150m cap or buyout. | on target | |
21/1/2020 15:32 | that's being pedantic! how long are you holding for? | purple11 | |
21/1/2020 15:30 | Spot the difference: ALL AML | on target | |
21/1/2020 15:24 | lion 12 months or so.2p 3p its allthe same to me I want to see the price when theyre testing in monkeys and phase 1.it will be nowhere near here.gl | purple11 | |
21/1/2020 15:02 | 30th May 2019 7:00 am RNS Hemogenyx Pharma Plc - CDX Antibody is Effective against ALL in vitro 5th Jun 2019 8:15 am RNS Hemogenyx Pharma Plc - CDX Antibody is Effective against AML in vivo | purple11 | |
21/1/2020 15:00 | yes it was bottomcat. | purple11 | |
21/1/2020 14:55 | No it wasnt purple,...you are such a muppett | johntopdog | |
21/1/2020 14:50 | So how long do you intend holding purple11 to see a healthy profit? I was assured that SXX was a sure thing 18 months ago but fortunately only dipped my toes in and got out quick. | lionheart69uk1 | |
21/1/2020 14:07 | last yr it was only a week or so after announcing cdx worked in vitro that they then announced it worked in vivo so an update on car t could come very quickly. | purple11 | |
21/1/2020 13:55 | one of the first successes with car t therapy | purple11 | |
21/1/2020 13:46 | this is how weve come.the inflection point is just round the corner now imo scaramouche1941 15 Jan '20 - 21:03 - 3485 of 3486 0 1 0 As far as I know a normal progression in the drug development is 1. Target identification, 2. Target validation, 3. Molecule (antibody discovery, cell construction etc)design, 4. in vitro efficacy, 5. in vivo efficacy, 6. IND-enabling studies, 7. IND, 8. Clinical trials It looks like Hemo went to IND enabling studies with their antibody and now they are repeating the same with CAR T. | purple11 | |
21/1/2020 13:25 | and I recently called the bottom here and heavily brought it so who cares what ppl think of me.i like the stock and believe it will be around a 40m cap company by the time it moves into phase 1 trials.which will be happening soon,probably this year. the price in the meantime is irrelevant to me unless I want to buy more as im not selling any at the moment,im buying. we all play our own game and I believe this has multibagger potential which is virtually impossible to buy on the market anywhere else at the moment.so I hold.one rns will put all these piddly trades to bed and ill make my money.the stock is so illiquid as we have recently seen,that when it comes the gains will be large.its along way up to a 40m cap. why does that mean my opinion is a scam? | purple11 | |
21/1/2020 13:16 | thanks a lot.i tried to make a thread where anyone could post,holders or not.i just don't want davet constantly slating the stock on my thread.MOST NORMAL PPL WHO DONT LIKE A STOCK SIMPLY MOVE TO ANOTHER THEY LIKE NOT CONSTANTLY TRY AND SLATE ANYONES OPINION BUT HIS OWN. THIS IS NOT A BIASED SCAM THREAD ITS A NORMAL THREAD. Christ! | purple11 | |
21/1/2020 13:11 | Purple, no wants to read your biased, self moderated, scam thread unfortunately Well I am happy to read this scam thread. It would be great if all sensible posters used this thread. However we do appear stuck with three threads currently. | nextlink | |
19/1/2020 13:35 | look at the numbers on this car-t phase 1 collaboration today, incl. €45m upfront, to put it into context hemo has a current mcap of 8m | purple11 | |
19/1/2020 13:29 | interesting post,the big gains lie ahead. scaramouche1941 15 Jan '20 - 21:03 - 3485 of 3486 0 1 0 As far as I know a normal progression in the drug development is 1. Target identification, 2. Target validation, 3. Molecule (antibody discovery, cell construction etc)design, 4. in vitro efficacy, 5. in vivo efficacy, 6. IND-enabling studies, 7. IND, 8. Clinical trials It looks like Hemo went to IND enabling studies with their antibody and now they are repeating the same with CAR T. I am impressed! All this for the money they raised when listed two years ago?!? This is crazy | purple11 | |
19/1/2020 13:25 | its great that there is more than one globalco collaborating with HEMO as it gives HEMO far better negotiating power going and a far greater chance of a great deal going forward.all super exciting now imo. | purple11 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions